(Q43039473)

12 November 2017

Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications (English)

1 reference

12 November 2017

P Pradat

1

1 reference

12 November 2017

H L Tillmann

2

1 reference

12 November 2017

S Sauleda

3

1 reference

12 November 2017

J-H Braconier

4

1 reference

12 November 2017

G Saracco

5

1 reference

12 November 2017

M Thursz

6

1 reference

12 November 2017

R Goldin

7

1 reference

12 November 2017

R Winkler

8

1 reference

12 November 2017

A Alberti

9

1 reference

12 November 2017

J-I Esteban

10

1 reference

12 November 2017

S Hadziyannis

11

1 reference

12 November 2017

M Rizzetto

12

1 reference

12 November 2017

H Thomas

13

1 reference

12 November 2017

M P Manns

14

1 reference

12 November 2017

C Trepo

15

1 reference

12 November 2017

HENCORE Group

16

1 reference

12 November 2017

1 August 2007

1 reference

Journal of Viral Hepatitis

12 November 2017

1 reference

12 November 2017

14

1 reference

12 November 2017

556-563

1 reference

12 November 2017

8

1 reference

Natural history and predictors of disease severity in chronic hepatitis C.

12 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Impact of hepatitis C virus infection on healthy subjects on an Italian island

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

HCV persistence: cure is still a four letter word

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Prevention of hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00829.X

10.1111/J.1365-2893.2006.00829.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference